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Each year, more than a half-million infants are born 
prematurely in the United States. Many of these preemies, 
particularly those whose tiny digestive systems are simply 
too underdeveloped to handle mother’s milk or infant for-
mula, may need to be nourished exclusively via intravenous 
feeding, known as “total parenteral nutrition,” or TPN.
TPN solutions, usually administered at the hospital for 
anywhere from a few days to a month or more, provide es-
sential nutrients broken down into a very basic form. This 
liquid is gently and continuously infused into the infant’s 
bloodstream, completely bypassing the digestive tract.
“TPN helps save the lives of newborns and supports 
their growth and development, especially of the brain,” 
says Douglas G. Burrin, an Agricultural Research Service 
physiologist at the Children’s Nutrition Research Center in 
Houston, Texas, and a faculty member at Baylor College 
of Medicine, also in Houston.
But preemies who are on TPN for longer than 2 weeks 
may develop complications that might affect their health 
later in life. Since 1998, Burrin and colleague Barbara 
Stoll, who is also with the nutrition center and the college 
faculty, have worked with teams of scientists in the United 
States and abroad to discover more about the unwanted side 
effects of TPN and to develop new, safe, effective ways to 
prevent these unintended consequences or, at the very least, 
to minimize their impact.
The TPN-linked problems that their research targets 
include poor control of blood sugar, slowed growth of the 
digestive tract, and onset of a constellation of disorders 
referred to as “parenteral nutrition-associated liver disease.”
In these investigations, Burrin and colleagues use piglets 
as their laboratory animal model.
Why Piglets?
Nutrition researchers worldwide recognize that the pig 
digestive tract is very similar to 
that of humans. Also, the size 
and body composition, that is, 
the amount of fat and amount of 
lean tissue, of an infant piglet “are 
typically comparable to those of 
a human preemie,” says Burrin. 
“Infant lab mice or newborn lab 
rats are simply too small for this 
research.”
Does TPN Increase Risk of Insulin Resistance?
In 2005, scientists elsewhere suggested an association between 
premature birth and increased risk of insulin resistance, a disorder 
common in type 2 diabetics.
A 2010 study by Burrin, Stoll, and others brought TPN into this 
picture. Their research provided the first evidence, in a newborn-lab-
animal model, of a significant association between TPN feeding and 
several indicators of insulin resistance.
In people, and in piglets, insulin—a hormone—largely controls the 
amount of sugar (glucose) in the bloodstream. Insulin is produced 
exclusively by unique “beta cells” in the pancreas. As it circulates 
through the body, insulin triggers cells to remove glucose from blood 
and use it for energy. But resistance to insulin can lead to a buildup of 
unhealthy levels of glucose in the blood.
Insulin resistance was 40 percent greater in the TPN-fed piglets than 
in their orally fed counterparts, the scientists found. Also of concern: 
Proliferation of beta cells was 30 
percent less in the TPN piglets.
“The beta cells that you pro-
duce during infancy and child-
hood have to last you a lifetime,” 
says Burrin, “so anything that 
interferes with normal beta-cell 
production could be detrimental 
to your later health. “
GLP-1 Levels: How Important 
Are They?
Followup research, reported 
by Burrin, Stoll, and others in 
2012, again indicated that insulin 
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At the Children’s Nutrition Research Center in Houston, Texas, ARS physiologist 
and professor of pediatrics Doug Burrin (left) and associate professor of pediatrics 
Darryl Hadsell examine a microscope image of pancreatic beta cells obtained from 
piglets fed by total parenteral nutrition.
Compared to human preemies, 
infant piglets are similar in size and 
body composition and have similar 
digestive tracts. These healthy piglets 
are about an hour old.
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resistance was significantly greater in TPN-
fed piglets, compared to piglets that were 
put on other feeding regimens.
In addition, the study suggested that 
reduced production of GLP-1 (glucagon-
like peptide 1), a hormone secreted in 
the digestive tract, may help explain the 
difference in insulin resistance among the 
research piglets.
Previous research has shown that GLP-
1, a “gut hormone,” circulates through the 
body and helps lessen insulin resistance. 
It belongs to a class of hormones known 
as “incretins.” Their insulin-regulating 
role, dubbed the “incretin effect,” has led 
to development of synthetic incretins now 
used in treatment of type 2 diabetes.
Says Burrin, “We found that plasma 
levels of GLP-1 were significantly lower 
in the TPN piglets than in any of the other 
piglet groups. That makes sense, given that 
there was no food in the TPN piglets’ diges-
tive tracts to stimulate secretion of GLP-1.
“We are continuing to investigate GLP-1 
in our research because we think there’s 
much more to be learned about it in the 
context of preventing or reducing insulin 
resistance in TPN infants.”
Small Doses of Bile Acid May Blunt  
Liver Disease
Gut hormones were also key in a study 
of a potential new approach to preventing 
parenteral nutrition-associated liver disease 
(PNALD).
PNALD is an umbrella term that en-
compasses several conditions, including 
cholestasis, which results from a buildup 
of excess bile acids in the liver, and steato-
sis, which—as its “fatty liver” nickname 
implies—occurs when there is too much 
fat in the liver.
There is no well-established, 
science-based cure for PNALD. 
In severe cases, this disease can 
lead to liver failure and the need 
for a liver transplant—a major 
surgery that, though not new, is 
still regarded as having consider-
able risks.
A team of Burrin, Stoll, and 
coinvestigators showed that giv-
ing newborn TPN-fed piglets a 
very small dose of a natural bile 
acid three times a day helped 
combat PNALD.
The acid, CDCA (chenodeoxycholic 
acid) is one of the major bile acids that are 
produced in the liver, then secreted—via the 
gall bladder and bile duct—into the upper 
digestive tract to help the body digest fat.
According to Burrin, the CDCA study 
is the first to demonstrate the use of small 
doses of this bile acid, delivered directly to 
the upper digestive tract, to control PNALD 
in a newborn-lab-animal model.
TPN piglets that were given CDCA 
had significantly lower levels of serum 
bilirubin, a biomarker of cholestasis, than 
did the TPN-fed piglets that were given a 
placebo. In addition, levels of serum bile 
acids, which are another biomarker of cho-
lestasis, and levels of liver triglycerides, an 
indicator of steatosis, were nearly normal 
in the CDCA-treated TPN piglets.
The team also found that CDCA stimu-
lated growth of mucosa, the inner lining of 
the intestine. That is significant. Explains 
Burrin, “TPN often has the exact opposite 
effect: It can lead to atrophy of the mucosa.” 
The shriveling and shrinking of the intestine 
that result can diminish the body’s ability 
to digest and absorb nutrients.
The researchers are now taking a closer 
look at the basic mechanisms responsible 
for the beneficial effects of the CDCA regi-
men. CDCA’s ability—as shown in mice—
to indirectly induce secretion of key gut 
hormones such as GLP-2 (glucagon-like 
peptide 2) and FGF19 (fibroblast growth 
factor 19) “may provide an explanation for 
some of our piglet findings,” Burrin says.
For example, previous research, includ-
ing that by Burrin and Stoll, has shown that 
GLP-2 boosts growth and proliferation of 
intestinal mucosal cells in piglets and in 
adult humans. In this newer study, reported 
in 2012, three factors—GLP-2 levels, better 
mucosal growth, and CDCA treatment—
appeared to be interrelated. That’s because 
TPN piglets that were treated with CDCA 
had higher levels of GLP-2 in their plasma. 
Those same piglets had better mucosal 
growth than the other TPN piglets.
FGF19 may also be an important part 
of the picture. In mice, FGF19 has the 
protective effect of suppressing produc-
tion of bile acids in the liver, in response 
to signals sent from specialized bile-acid-
sensing cells in the gut. CDCA-treated TPN 
piglets had healthier bile acid levels, and 
more FGF19 in their plasma, than did the 
other TPN-fed piglets.
Piglets that were not on a TPN regimen 
had the highest plasma FGF19 levels. “We 
regard this finding as strong evidence that 
TPN suppresses secretion of FGF19, which 
results in disruption of normal regulation 
of bile acids. We think this suppression is 
a key piece of the puzzle of why and how 
TPN can cause liver disease.”
Burrin and Stoll, along with Teresa 
A. Davis, Darryl L. Hadsell, and David 
D. Moore, all of the nutrition center 
research staff and Baylor College of 
Medicine faculty, and other collaborators, 
have documented their TPN findings in 
peer-reviewed articles in the Journal of 
Nutrition, the American Journal of Paren-
teral and Enteral Nutrition, the American 
Journal of Physiology: Gastrointestinal 
and Liver Physiology, and other scientific 
publications. The American Society for 
Parenteral and Enteral Nutrition, the Na-
tional Institutes of Health, the American 
Liver Foundation, and ARS funded the 
studies.—By Marcia Wood, ARS.
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Research instructor of pediatrics 
Barbara Stoll (left) and assistant 
Liwei Cui fill parenteral nutrition 
bags with formulas to nourish 
infant piglets.
STEPHEN AUSMUS (D2850-10)
